References
- Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med.353(5), 487–497 (2005).
- Hughes CM. Medication nonadherence in the elderly: how big is the problem? Drugs Aging21(12), 793–811 (2004).
- MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging22(3), 231–255 (2005).
- Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA. Understanding medication compliance and persistence from an economics perspective. Value Health11(4), 600–610 (2008).
- Metcalfe R. Compliance, adherence, concordance – what is in a name? Practical Neurol.5, 192–193 (2005).
- World Health Organization (WHO). Adherence to Long-Term Therapies. Evidence for Action. WHO, Geneva, Switzerland (2003).
- Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am. J. Geriartr. Psychiatry6(2, Suppl. 1), S3–S18 (1998).
- Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr. Med. Res. Opin.23(11), 2705–2713 (2007).
- Cummings JL, Frank JC, Cherry D et al. Guidelines for managing Alzheimer’s disease: part II. Treatment. Am. Fam. Physician65(12), 2525–2534 (2002).
- Guay DR. Rivastigmine transdermal patch: role in the management of Alzheimer’s disease. Consult. Pharm.23(8), 598–609 (2008).
- Yang LP, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type. CNS Drugs21(11), 957–965 (2007).
- Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int. J. Clin. Pract.63(5), 799–805 (2009).
- Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry22(5), 456–467 (2007).
- Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr. Med. Res. Opin.23(12), 3199–3204 (2007).
- Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res.12(3), 189–198 (1975).
- Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry139(9), 1136–1139 (1982).
- Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J. Psychiatr. Pract.15(1), 34–44 (2009).
- Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs23(4), 293–307 (2009).
- Schmidt R, Alf C, Bancher C et al. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia]. Neuropsychiatr.23(1), 58–63 (2009).
- Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL. Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands. Tijdschr. Gerontol. Geriatr.41(3), 146–150 (2010).
- Burris JF, Papademetriou V, Wallin JD, Cook ME, Weidler DJ. Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. Am. J. Med.91(1A), S22–S28 (1991).
- Bernabei R, Martínez-Lage P. Clinical benefits associated with a transdermal patch for dementia. Eur. Neurol. Dis.3(1), 10–13 (2008).
- Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl.25, 122–123 (2002).
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296 (2001).